These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32936748)

  • 41. Critical issues for effective collaboration between academia and industry in the field of regenerative medicine in Japan.
    Tsubouchi M; Morishita R; Tabata Y; Matsui S; Kawakami K
    Regen Med; 2008 Jul; 3(4):497-504. PubMed ID: 18588472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
    Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
    Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Indian vaccine innovation: the case of Shantha Biotechnics.
    Chakma J; Masum H; Perampaladas K; Heys J; Singer PA
    Global Health; 2011 Apr; 7():9. PubMed ID: 21507259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Academic-industry Collaborations in Translational Stroke Research.
    Boltze J; Wagner DC; Barthel H; Gounis MJ
    Transl Stroke Res; 2016 Aug; 7(4):343-53. PubMed ID: 27301976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation of sustainable complex interventions in health care services: the triple C model.
    Khalil H; Kynoch K
    BMC Health Serv Res; 2021 Feb; 21(1):143. PubMed ID: 33588823
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate.
    Ferris MJ; Sun K; Savard C; Suresh T; Mishra MV
    Cureus; 2021 Sep; 13(9):e18210. PubMed ID: 34692353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medicine and pharmacy--facts and myths about the development of an innovative pharmaceutical industry in Poland.
    Kubiak W
    Sci Eng Ethics; 2005 Jan; 11(1):41-51. PubMed ID: 15726998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Innovation at the Interface between Academia and Industry: The BioMed X Model.
    Cristian FB; Tidona C; Rückle T
    Handb Exp Pharmacol; 2024 Sep; ():. PubMed ID: 39235485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Employment of the Triple Helix concept for development of regenerative medicine applications based on human pluripotent stem cells.
    Sartipy P; Björquist P
    Clin Transl Med; 2014; 3():9. PubMed ID: 24872863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Collective action for implementation: a realist evaluation of organisational collaboration in healthcare.
    Rycroft-Malone J; Burton CR; Wilkinson J; Harvey G; McCormack B; Baker R; Dopson S; Graham ID; Staniszewska S; Thompson C; Ariss S; Melville-Richards L; Williams L
    Implement Sci; 2016 Feb; 11():17. PubMed ID: 26860631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug use in academic medical centres in an era of ferment.
    Avorn J
    Pharmacoeconomics; 1996; 10 Suppl 2():124-9. PubMed ID: 10163429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Igniting Innovation in Healthcare: A Novel Collaborative Multidisciplinary Approach in a PICU.
    Malakooti MR
    Pediatr Crit Care Med; 2018 Jul; 19(7):e374-e377. PubMed ID: 29652751
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
    Finch R; Hunter PA
    J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry.
    Buck E; Mulvihill M; Iwata KK
    Mt Sinai J Med; 2010; 77(4):358-65. PubMed ID: 20687181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Academic-Pharma drug discovery alliances: seeking ways to eliminate the valley of death.
    Hammonds T
    Future Med Chem; 2015; 7(14):1891-9. PubMed ID: 26393391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient Centricity and Pharmaceutical Companies: Is It Feasible?
    du Plessis D; Sake JK; Halling K; Morgan J; Georgieva A; Bertelsen N
    Ther Innov Regul Sci; 2017 Jul; 51(4):460-467. PubMed ID: 30227057
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.